



Certificate of Mailing (37 C.F.R. §1.8):

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to:
Commissioner for Patents,
PO Box 1450, Alexandria, VA 22313-1450
on this ^{5th} day of November 2003.

s/

Julie Agozino

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:
PAUL JOHN EDWARDS, ET. AL.

Serial No.: 10/657,033

Confirmation No.: TBA

Filed: September 5, 2003

For: PYRAZOLE DERIVATIVES

Group Art Unit: TBA

Examiner: TBA

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97(b)

Commissioner For Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to the duty of disclosure under 37 CFR 1.56, Applicant brings the documents listed on the attached substitute Form PTO-1449 to the attention of the Examiner for consideration in connection with the examination of the above-identified application.

This Information Disclosure Statement is being filed within the period specified in 37 CFR 1.97(b)-i.e., (1) within three months of the filing date of the national application, (2) within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application, or (3) to the undersigned's knowledge, before the mailing date of a first Office Action on the merits, whichever event occurs last.

It is respectfully requested that the Examiner confirm consideration of the cited documents by initialing the attached substitute Form PTO-1449 and returning a copy of the initialed form to the Applicant.

If any fees are due in connection with the filing of this statement, including the fee set forth in 37 CFR 1.17(p) in the event that the period specified in 37 CFR 1.97(b) has elapsed, please charge all required fees to Deposit Account No. 500329.

Respectfully submitted,


Date: Nov. 04, 2003

Keith D. Hutchinson
Keith D. Hutchinson
Attorney For Applicant
Registration No. 43,687

Agouron Pharmaceuticals, Inc./A Pfizer Company
Patent Department
10777 Science Center Drive
San Diego, California 92121
Phone: (858) 526-4608
Fax: (858) 678-8233

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/657,033
Filing Date	September 5, 2003
First Named Inventor	Paul John Edwards
Art Unit	TBA
Examiner Name	TBA
Attorney Docket Number	PC25402A

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	Cite No. ¹	DOCUMENT NUMBER	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ²			
	AA	60/432,781	12-11-02	Pfizer Inc.	
	AB	6,586,430	07-01-2003	Pfizer, Inc.	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁵
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
	AC	UK 0223234.6	06-04-03	Pfizer Limited		
	AD	WO 91/11172	08-08-1991	The University of Kansas		
	AE	WO 94/02518	02-03-1994	The University of Kansas		
	AF	WO 98/55148	12-10-1998	Janssen Pharmaceutica		
	AG	WO 02/04424 A1	01-17-2002	Pfizer Limited		
	AH	WO 02/30907 A1	04-18-2002	F. Hoffmann-La Roche		

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

Complete if Known

Application Number	10/657,033
Filing Date	September 5, 2003
First Named Inventor	Paul John Edwards
Art Unit	TBA
Examiner Name	TBA
Attorney Docket Number	PC25402A

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AI	BERGE, et al., "Pharmaceutical Salts," <i>Journal of Pharmaceutical Sciences</i> , 1977, 1-19, vol. 66, No. 1.	
	AJ	BIGHLEY, et al., "Salt Forms of Drugs and Absorption," <i>Encyclopedia of Pharmaceutical Technology</i> , Marcel Dekker Inc. New York, 1996, pages 453-497, vol. 13.	
	AK	BUNDGAARD, H., <i>Design of Prodrugs</i> , 1985, Elsevier Science Publishers, Amsterdam, New York, Oxford.	
	AL	CAREY, et al., "Part A: Structure and Mechanisms," <i>Advanced Organic Chemistry</i> , 3 rd Edition, Plenum Press, New York, London.	
	AM	FERRES, et. al., "Pro-Drugs of β -Lactam Antibiotics," <i>Drugs of Today</i> 1983, 499-538, Vol. 19, No. 9.	
	AN	GENIN, M. et al., "Novel 1,5-Diphenylpyrazole Nonnucleoside HIV-1 Reverse Transcriptase Inhibitors with Enhanced Activity Versus The Delavirdine-Resistant P236L Mutant: Lead Identification and SAR of 3- and 4-Substituted Derivatives," <i>Journal of Medicinal Chemistry</i> , 2000, vol. 43, page 1034-1040.	
	AO	GREENE, T. <i>Protective Groups In Organic Synthesis</i> 2 nd Edition 1991, John Wiley & Sons, Inc., New York, Chichester, Brisbane, Toronto, Singapore.	
	AP	HAJIMORAD, et al., "Some Observations On The Binding Properties Of Alfalfa Mosaic Virus To Polystyrene And Its Significance To Indirect ELISA," <i>Archives of Virology</i> , 1991, pages 219-235, Vol. 117.	
	AQ	KATRITZKY, et al. "The Structure, Reactions, Synthesis and Uses of Heterocyclic Compounds," <i>Comprehensive Heterocyclic Chemistry</i> Vol. 1-11, Pergamon Press, Oxford, New York, Toronto, Sydney, Paris, Frankfurt.	

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.